Adulsa Therapeutics
Berwyn, US · Founded 2020 · Delaware corporation
Find your way into Adulsa Therapeutics
Sign up to see every warm intro you have to Adulsa Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Adulsa Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
AM
Andrew MorozovNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$525K disclosed across 1 round · 2021
▶$525KraisedOct 2021 · 2 investors · Biotechnology
▶$525KraisedOct 2021 · 2 investors · Biotechnology
Officers, directors & promoters on the filing
- Andrew MorozovExecutive Officer
- Offering amount
- $3.5M
- Amount sold
- $525K
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 04
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Adulsa Therapeutics raised?
- Adulsa Therapeutics has disclosed $525K raised across 1 round.
- Where is Adulsa Therapeutics headquartered?
- Adulsa Therapeutics is headquartered in Berwyn, US.